克隆性造血与无症状华氏巨球蛋白血症进展风险增加相关
该研究在587例IgM意义未明的单克隆丙种球蛋白病(MGUS)、冒烟型华氏巨球蛋白血症(SWM)或华氏巨球蛋白血症(WM)患者中检测DNMT3A、TET2或ASXL1(DTA)体细胞突变定义的克隆性造血(CH),发现CH患病率为14%,DTA克隆的存在和大小与年龄较大相关,CH患者从MGUS或SWM进展为WM的风险增加,但总生存未变差。
要点
- 在587例IgM MGUS、SWM或WM患者中,CH(DTA突变)患病率为14%。
- DTA克隆的存在和大小与年龄较大相关。
- CH患者从MGUS或SWM进展为WM的风险增加,但总生存未变差。
核心结论
- CH患者从MGUS或SWM进展为WM的风险增加,但未观察到总生存变差。
研究设计与样本
- 研究纳入587例IgM MGUS、SWM或WM患者,CH定义为DNMT3A、TET2或ASXL1(DTA)体细胞突变。
主要发现
- CH在587例患者中的患病率为14%。
- DTA克隆的存在和大小与年龄较大相关。
- CH患者从MGUS或SWM进展为WM的风险增加,但总生存未变差。
关键数值与推荐
- CH定义为DNMT3A、TET2或ASXL1(DTA)体细胞突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal hematopoiesis (CH) is associated with adverse outcomes in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma undergoing autologous stem cell transplantation. Still, its implications for patients with indolent NHL have not been well studied. We report the prevalence of CH in patients with Waldenström macroglobulinemia (WM) and its association with clinical outcomes. To unambiguously differentiate CH mutations from those in the WM clone, CH was defined by the presence of somatic mutations in DNMT3A, TET2, or ASXL1 (DTA) and was detected in 14% of 587 patients with IgM monoclonal gammopathy of undetermined significance (MGUS), smoldering WM (SWM) or WM. The presence and size of DTA clones were associated with older age. Patients with CH had an increased risk of progression from MGUS or SWM to WM, but not worse overall survival in this cohort. These findings further illuminate the clinical effects of CH in patients with indolent NHL such as WM.
引用
- Tahri S, Mouhieddine TH, Redd R, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022. PMID: 34847227. doi:10.1182/bloodadvances.2021004926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。